Evidence map›Paper›PMID 40631283›Full record

ArticlebioRxiv : the preprint server for biology2025

Genome-wide extraction of differentially methylated DNA regions using adapter-anchored proximity primers.

Farzaneh Darbeheshti, Hayet Radia Zeggar, Hamzeh Salmani, Yibin Liu, Ruolin Liu, Viktor A Adalsteinsson, G Mike Makrigiorgos

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Farzaneh DarbeheshtiDana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0002-4957-9004
Hayet Radia ZeggarDana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.
Hamzeh SalmaniDana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.
Yibin LiuState Key Laboratory of Metabolism and Regulation in Complex Organisms, College of Chemistry and Molecular Sciences, Taikang Center for Life and Medical Sciences, Wuhan University, Wuhan, China.
Ruolin LiuBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.ORCID 0000-0001-9059-6335
Viktor A AdalsteinssonBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
G Mike MakrigiorgosDana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.

Funding

Comprehensive minimal residual disease tracking in cancerR01CA221874 · NCI · DANA-FARBER CANCER INST · PI Viktor Adalsteinsson, G. Mike Makrigiorgos · 2018 to 2026
$2.5M
NCI NIH HHS R01 CA221874
6 · The paper itself

Abstract

The epigenetic deregulation of CpG islands (CGIs) plays a crucial role in cancer initiation and progression. CGIs comprise 1-2% of the human genome and are rich in differentially methylated regions (DMRs) that can serve as cancer biomarkers in clinical samples and liquid biopsies. Focusing epigenetic sequencing on CpG-rich sequences, including CGIs and avoiding non-informative regions, offers an efficient and sensitive approach for cancer identification and tracking, especially within samples containing excess of unaltered, normal DNA. To this end, we have developed Adaptor-anchored Methylation amplification via Proximity Primers (aMAPP), a versatile PCR-based enrichment method. aMAPP employs specially designed primers to selectively enrich either methylated or unmethylated CpGs, depending on the upstream methylation conversion method employed. aMAPP achieves high coverage of genome-wide CGIs and detects hundreds of DMRs in tumor samples compared to adjacent normal tissue using ultra-low depth sequencing (~300,000 reads). It enables tracing of aberrant methylation down to allelic frequency 0.01% in dilutions of tumor DNA and in cell-free DNA samples, can be applied using picogram amounts of DNA, and can be adapted to enrich either small panels of cancer-specific DMRs, or the majority (>90%) of genomic CGIs and CpGs. aMAPP offers a simple, cost-effective, and highly sensitive approach for capturing the epigenetic footprint of genome-wide CpGs and identifying aberrantly methylated or un-methylated genomic regions.

Identifiers

PMID40631283
PMCPMC12236785

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.